Matches in SemOpenAlex for { <https://semopenalex.org/work/W2185087206> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2185087206 abstract "Introduction: The influence of induction therapy (corticosteroids, immunosuppressive agents) used in active phase systemic lupus erythematosus (SLE) patients (pts) on the antiphospholipid antibodies (aPL) remains not fully explained. Objective: Therefore, the aim of the study was the assessment of induction therapy effects on the level of the aPLs in active SLE pts. Material and Methods: Sixty eight consecutive (56 F, 12 M), active SLE pts, mean age 38,3±13,7, entered the study. Patients received high dose steroids and/or cytotoxics: intravenous methylprednisolone pulses + oral steroids in period between pulses (24 pts), intravenous cyclophosphamide pulses + oral steroids in period between pulses (13 pts), intravenous cyclophosphamide, methylprednisolone pulses + oral steroids in period between pulses (14 pts) and oral azathioprine + methylprednisolone pulses + oral steroids (17 pts). Activity of SLE was assessed by Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). Before intensification of the treatment (0), after 3 (3), 6 (6) and 9 (9) months of the therapy the pts were examined for the presence of the following aPL antibodies: antibodies to cardiolipin (acl) in IgM and IgG class, anti-β2 glycoprotein I (a-B2GPI) in IgM and IgG class. The acl and a-B2GPI antibodies were determined by commercially available ELISA. Results: The acl in IgM class decreased in first 6 months of the treatment (0 vs. 3 P=0.0004 and 0 vs. 6 P=0.001). The acl in IgG class decreased after 3 months of the treatment (P=0.06). In period between 6 and 9 months of treatment concentrations of acl in IgM class and IgG class increased significantly. Antibodies a-β2 GPI in IgM and IgG class and SLEDAI-2K significantly decreased during the whole period of treatment (9 months). In conclusion, the induction immunosuppressive therapy used in active SLE pts significantly decreased the level of the antiphospholipid antibodies particularly in early period of treatment." @default.
- W2185087206 created "2016-06-24" @default.
- W2185087206 creator A5025955879 @default.
- W2185087206 creator A5046276884 @default.
- W2185087206 creator A5083037457 @default.
- W2185087206 date "2008-01-01" @default.
- W2185087206 modified "2023-09-25" @default.
- W2185087206 title "The influence of immunosuppressive therapy on the antiphospholipid antibodies level in active systemic lupus erythematosus patients - nine months study" @default.
- W2185087206 cites W1741477232 @default.
- W2185087206 cites W1976154467 @default.
- W2185087206 cites W1982207491 @default.
- W2185087206 cites W2012049363 @default.
- W2185087206 cites W2049127318 @default.
- W2185087206 cites W2061975883 @default.
- W2185087206 cites W2068106248 @default.
- W2185087206 cites W2120568843 @default.
- W2185087206 hasPublicationYear "2008" @default.
- W2185087206 type Work @default.
- W2185087206 sameAs 2185087206 @default.
- W2185087206 citedByCount "0" @default.
- W2185087206 crossrefType "journal-article" @default.
- W2185087206 hasAuthorship W2185087206A5025955879 @default.
- W2185087206 hasAuthorship W2185087206A5046276884 @default.
- W2185087206 hasAuthorship W2185087206A5083037457 @default.
- W2185087206 hasConcept C126322002 @default.
- W2185087206 hasConcept C159654299 @default.
- W2185087206 hasConcept C203014093 @default.
- W2185087206 hasConcept C2775915377 @default.
- W2185087206 hasConcept C2776694085 @default.
- W2185087206 hasConcept C2776755627 @default.
- W2185087206 hasConcept C2776760755 @default.
- W2185087206 hasConcept C2776912625 @default.
- W2185087206 hasConcept C2779134260 @default.
- W2185087206 hasConcept C2780372218 @default.
- W2185087206 hasConcept C71924100 @default.
- W2185087206 hasConcept C90924648 @default.
- W2185087206 hasConceptScore W2185087206C126322002 @default.
- W2185087206 hasConceptScore W2185087206C159654299 @default.
- W2185087206 hasConceptScore W2185087206C203014093 @default.
- W2185087206 hasConceptScore W2185087206C2775915377 @default.
- W2185087206 hasConceptScore W2185087206C2776694085 @default.
- W2185087206 hasConceptScore W2185087206C2776755627 @default.
- W2185087206 hasConceptScore W2185087206C2776760755 @default.
- W2185087206 hasConceptScore W2185087206C2776912625 @default.
- W2185087206 hasConceptScore W2185087206C2779134260 @default.
- W2185087206 hasConceptScore W2185087206C2780372218 @default.
- W2185087206 hasConceptScore W2185087206C71924100 @default.
- W2185087206 hasConceptScore W2185087206C90924648 @default.
- W2185087206 hasLocation W21850872061 @default.
- W2185087206 hasOpenAccess W2185087206 @default.
- W2185087206 hasPrimaryLocation W21850872061 @default.
- W2185087206 hasRelatedWork W2007583611 @default.
- W2185087206 hasRelatedWork W2052627441 @default.
- W2185087206 hasRelatedWork W2073213473 @default.
- W2185087206 hasRelatedWork W2155767262 @default.
- W2185087206 hasRelatedWork W2359594492 @default.
- W2185087206 hasRelatedWork W2384613954 @default.
- W2185087206 hasRelatedWork W2391866783 @default.
- W2185087206 hasRelatedWork W2409050988 @default.
- W2185087206 hasRelatedWork W2460218540 @default.
- W2185087206 hasRelatedWork W2515112954 @default.
- W2185087206 hasRelatedWork W2743252822 @default.
- W2185087206 hasRelatedWork W2754307774 @default.
- W2185087206 hasRelatedWork W2790763924 @default.
- W2185087206 hasRelatedWork W2808342697 @default.
- W2185087206 hasRelatedWork W2984634561 @default.
- W2185087206 hasRelatedWork W2992403397 @default.
- W2185087206 hasRelatedWork W3043447285 @default.
- W2185087206 hasRelatedWork W3080414777 @default.
- W2185087206 hasRelatedWork W3169828957 @default.
- W2185087206 hasRelatedWork W3187586413 @default.
- W2185087206 isParatext "false" @default.
- W2185087206 isRetracted "false" @default.
- W2185087206 magId "2185087206" @default.
- W2185087206 workType "article" @default.